

OSCIENT PHARMACEUTICALS CORP  
Form 8-K  
April 14, 2004

---

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

## FORM 8-K

---

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): April 13, 2004

---

# GENOME THERAPEUTICS CORP.

(Exact name of registrant as specified in its charter)

---

Massachusetts  
(State or other jurisdiction  
of incorporation)

0-10824  
(Commission File Number)

04-2297484  
(I.R.S. Employer  
Identification Number)

100 Beaver Street  
Waltham, Massachusetts 02453

(Address of principal executive offices, including zip code)

**(781) 398-2300**

**(Registrant's telephone number, including area code)**

---

ITEM 5. OTHER EVENTS

On April 13, 2004, Genome Therapeutics Corp. issued a press release announcing that its shareholders had approved an amendment to the Company's Articles of Incorporation to change its name to Oscient Pharmaceuticals Corporation. A copy of the press release is attached hereto as Exhibit 99.1.

Item 7. FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits

99.1 Press Release issued by Genome Therapeutics Corp. on April 13, 2004.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENOME THERAPEUTICS CORP.

By: /s/ Stephen Cohen

Name: Stephen Cohen

Title: Senior Vice President and Chief Financial  
Officer

Date: April 13, 2004

EXHIBIT INDEX

**Exhibit Number**

---

**Description**

---

99.1

Press Release issued by Genome Therapeutics Corp. on April 13, 2004.